BAIT
TP53
BCC7, LFS1, P53, TRP53
tumor protein p53
GO Process (61)
GO Function (25)
GO Component (14)
Gene Ontology Biological Process
- DNA damage response, signal transduction by p53 class mediator [IDA, IMP]
- DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [TAS]
- DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator [IMP]
- DNA strand renaturation [IDA]
- ER overload response [IDA]
- Notch signaling pathway [TAS]
- Ras protein signal transduction [IEP]
- apoptotic process [TAS]
- base-excision repair [TAS]
- blood coagulation [TAS]
- cell aging [IMP]
- cell cycle arrest [IDA, IMP]
- cell differentiation [TAS]
- cell proliferation [TAS]
- cellular protein localization [IDA]
- cellular response to DNA damage stimulus [IDA]
- cellular response to UV [IBA]
- cellular response to drug [IEP]
- cellular response to glucose starvation [IDA]
- cellular response to hypoxia [IEP]
- cellular response to ionizing radiation [IMP]
- chromatin assembly [IDA]
- determination of adult lifespan [ISS]
- intrinsic apoptotic signaling pathway [TAS]
- intrinsic apoptotic signaling pathway by p53 class mediator [IMP]
- intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [IDA]
- mitotic G1 DNA damage checkpoint [IMP]
- multicellular organismal development [IMP]
- negative regulation of apoptotic process [IDA]
- negative regulation of cell growth [IMP]
- negative regulation of cell proliferation [ISS]
- negative regulation of fibroblast proliferation [IMP]
- negative regulation of helicase activity [TAS]
- negative regulation of transcription from RNA polymerase II promoter [IBA, IDA, ISS]
- negative regulation of transcription, DNA-templated [ISS]
- nucleotide-excision repair [IMP]
- oligodendrocyte apoptotic process [IDA]
- oxidative stress-induced premature senescence [IMP]
- positive regulation of apoptotic process [IDA]
- positive regulation of cell cycle arrest [IMP]
- positive regulation of histone deacetylation [IBA]
- positive regulation of intrinsic apoptotic signaling pathway [IMP]
- positive regulation of neuron apoptotic process [IBA]
- positive regulation of peptidyl-tyrosine phosphorylation [ISS]
- positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [TAS]
- positive regulation of protein oligomerization [IDA]
- positive regulation of reactive oxygen species metabolic process [IMP]
- positive regulation of release of cytochrome c from mitochondria [IDA]
- positive regulation of thymocyte apoptotic process [ISS]
- positive regulation of transcription from RNA polymerase II promoter [IDA, IGI, IMP]
- positive regulation of transcription, DNA-templated [IDA, IMP]
- protein complex assembly [IDA]
- protein localization [IDA]
- protein tetramerization [TAS]
- regulation of apoptotic process [IDA]
- regulation of mitochondrial membrane permeability [TAS]
- regulation of transcription, DNA-templated [IDA]
- replicative senescence [IMP]
- response to X-ray [IBA]
- response to antibiotic [IEP]
- response to gamma radiation [IMP]
Gene Ontology Molecular Function- ATP binding [IDA]
- DNA binding [IMP]
- RNA polymerase II transcription factor binding [IPI]
- RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription [IDA]
- chaperone binding [IPI]
- chromatin binding [IDA]
- copper ion binding [IDA]
- damaged DNA binding [IBA]
- enzyme binding [IPI]
- histone acetyltransferase binding [IPI]
- identical protein binding [IPI]
- p53 binding [IBA]
- protease binding [IPI]
- protein N-terminus binding [IPI]
- protein binding [IPI]
- protein heterodimerization activity [IPI]
- protein kinase binding [IPI]
- protein phosphatase 2A binding [IPI]
- protein phosphatase binding [IPI]
- receptor tyrosine kinase binding [IPI]
- sequence-specific DNA binding transcription factor activity [IDA]
- transcription factor binding [IPI]
- transcription regulatory region DNA binding [IDA]
- ubiquitin protein ligase binding [IPI]
- zinc ion binding [TAS]
- ATP binding [IDA]
- DNA binding [IMP]
- RNA polymerase II transcription factor binding [IPI]
- RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription [IDA]
- chaperone binding [IPI]
- chromatin binding [IDA]
- copper ion binding [IDA]
- damaged DNA binding [IBA]
- enzyme binding [IPI]
- histone acetyltransferase binding [IPI]
- identical protein binding [IPI]
- p53 binding [IBA]
- protease binding [IPI]
- protein N-terminus binding [IPI]
- protein binding [IPI]
- protein heterodimerization activity [IPI]
- protein kinase binding [IPI]
- protein phosphatase 2A binding [IPI]
- protein phosphatase binding [IPI]
- receptor tyrosine kinase binding [IPI]
- sequence-specific DNA binding transcription factor activity [IDA]
- transcription factor binding [IPI]
- transcription regulatory region DNA binding [IDA]
- ubiquitin protein ligase binding [IPI]
- zinc ion binding [TAS]
Gene Ontology Cellular Component
Homo sapiens
PREY
CD8A
CD8, Leu2, MAL, p32
CD8a molecule
GO Process (5)
GO Function (3)
GO Component (4)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
TP53 mutations are common in most human cancers, but few therapeutic options for TP53-mutant tumors exist. To identify potential therapeutic options for cancer patients with TP53 mutations, we profiled 127 FDA-approved chemotherapy drugs against human embryonic stem cells (hESC) in which we engineered TP53 deletion by genome editing. We identified 27 cancer therapeutic drugs for which TP53 mutations conferred resistance; ... [more]
Cancer Res Dec. 01, 2018; 79(9);2392-2403 [Pubmed: 30862715]
Throughput
- Low Throughput
Additional Notes
- CRISPR GI screen
- Cell Line: hESC
- Experimental Setup: Drug Exposure: Cisplatin CHEBI:27899
- GIST: Mono-phenotypic suppressing genetic interaction
- KO of hit genes re-sensitizes TP53 KO cells to cisplatin
- Library: GeckoV2
- Significance Threshold: p<0.01
Curated By
- BioGRID